SAFETY DATA SHEET
CLINTABS® Tablets

1. IDENTIFICATION

Product Name	CLINTABS® Tablets
Recommended use of the chemical and restrictions on use	
Identified uses	Antibiotic for use in dogs
Restrictions on Use	Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Company Identification	Virbac AH, Inc. P.O. Box 162059 Fort Worth, Texas 76161
Customer Information Number	(800) 338-3659
Emergency Telephone Number	
Chemtrec Number	(800) 424-9300
Other Emergency Number:	Poison Control Center: 1-800-222-1222 (human) HOT LINE NUMBER: 1-800-345-4735 (human and pet)
Issue Date	February 6, 2017
Supersedes Date	January 30, 2012

Safety Data Sheet prepared in accordance with OSHA's Hazard Communication Standard (29 CFR 1910.1200) and the Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

2. HAZARDS IDENTIFICATION

Hazard Classification
This product is classified as not hazardous in accordance with the Globally Harmonized System of Classification and Labelling (GHS).

Label Elements
Hazard Symbols
None

Signal Word: None

Hazard Statements
None

Precautionary Statements
Prevention
None
Response
None
Storage
None
Disposal
None

Other Hazards
None

2. HAZARDS IDENTIFICATION

Specific Concentration Limits
The values listed below represent the percentages of ingredients of unknown toxicity.

Acute oral toxicity	<10%
Acute dermal toxicity	60 - 70%
Acute inhalation toxicity	>90%
Acute aquatic toxicity	>90%

3. COMPOSITION/INFORMATION ON INGREDIENTS

Synonyms:
This product is a mixture.

Component Name	CAS Number	Concentration
Clindamycin Hydrochloride	58207-19-5	40 - 50%

4. FIRST AID MEASURES

Description of necessary first-aid measures
Eyes
Not an expected route of entry. If tablet contacts eye, flush thoroughly with water. If pain or irritation persists contact a physician.
Skin
If irritation develops wash skin thoroughly with soap and water. Obtain medical attention if redness or soreness persists.
Ingestion
Call a poison control center or doctor immediately for treatment advice. Do not induce vomiting unless told to do so by a poison control center or doctor. Do not give anything by mouth to an unconscious person.
Inhalation
Remove person to fresh air. Seek medical attention if symptoms persist.

Most important symptoms/effects, acute and delayed
Aside from the information found under Description of necessary first aid measures (above) and Indication of immediate medical attention and special treatment needed, no additional symptoms and effects are anticipated.

Indication of immediate medical attention and special treatment needed
Notes to Physicians
Treat symptomatically.

5. FIRE - FIGHTING MEASURES

Extinguishing Media
Use extinguishing media appropriate for surrounding materials.

Unusual Fire and Explosion Hazards
Can release hazardous vapors during a fire.

Protective Equipment for Fire-Fighting
Wear full protective clothing and self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures
No specific measures recommended.

Environmental Precautions
Prevent the material from entering drains or watercourses.

Methods and materials for containment and cleaning up
Pick up and dispose of in accordance with all applicable local and national regulations. Prevent the material from entering drains or watercourses.

7. HANDLING AND STORAGE

Precautions for safe handling
Wear appropriate protective clothing.

Conditions for safe storage
Store in original container at temperatures between 68˚F and 77˚F (20˚C - 25˚C). Store away from children and pets.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters
Exposure limits are listed below, if they exist.

Appropriate engineering controls
No specific measures necessary. Good general room ventilation is expected to be adequate to control airborne levels.

Individual protection measures
Respiratory Protection
Not required under normal conditions of use.
Skin Protection
Not required under normal conditions of use.
Eye/Face Protection
Not required under normal conditions of use.
Body Protection
Normal work wear

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical State	Solid (tablet)
Color	Off-white to tan
Odor	None
Odor Threshold	No data available
pH	No data available
Relative Density	No data available
Boiling Range/Point (°C/F)	No data available
Melting Point (°C/F)	No data available
Flash Point (PMCC) (°C/F)	Not flammable
Vapor Pressure	No data available

9. PHYSICAL AND CHEMICAL PROPERTIES

Evaporation Rate (BuAc=1)	No data available
Solubility in Water	No data available
Vapor Density (Air = 1)	No data available
VOC	No data available
Partition coefficient (n-octanol/water)	Not applicable
Viscosity	Not applicable
Auto-ignition Temperature	No data available
Decomposition Temperature	No data available
Upper explosive limit	No data available
Lower explosive limit	No data available
Flammability (solid, gas)	No data available

10. STABILITY AND REACTIVITY

Reactivity
Data is not available

Chemical Stability
Stable under normal conditions.

Possibility of hazardous reactions
Hazardous polymerization will not occur.

Conditions to Avoid
Heat - high temperatures

Incompatible Materials
None known.

Hazardous Decomposition Products
Oxides of carbon – nitrogen oxides

11. TOXICOLOGICAL INFORMATION

Acute Toxicity
Clindamycin Hydrochloride
Oral LD50 (rat) 2619 mg/kg

Specific Target Organ Toxicity (STOT) – single exposure
Clindamycin: Ingestion of large quantities of this material may cause gastrointestinal effects such as nausea, vomiting, diarrhea, and abdominal cramps.

Specific Target Organ Toxicity (STOT) – repeat exposure
Clindamycin: Ingestion at therapeutic doses can cause adverse gastrointestinal and liver effects.

Serious Eye damage/Irritation
Not an expected route of entry during normal handling and use.

Skin Corrosion/Irritation
Contact with skin is not expected to cause adverse effects.

11. TOXICOLOGICAL INFORMATION

Respiratory or Skin Sensitization
Clindamycin: Ingestion can cause allergic reaction in individuals hypersensitive to clindamycin and lincomycin.

Carcinogenicity
Not considered carcinogenic by NTP, IARC, and OSHA.

Germ Cell Mutagenicity
Clindamycin: Genotoxic effects of topical clindamycin were negative in the human lymphocyte chromosome aberration test and when evaluated with a rat micronucleus test and an Ames test.

Reproductive Toxicity
Clindamycin: Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (3.2 and 1.6 times the highest recommended adult human dose based on mg/m2, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (1.3 and 0.7 times the highest recommended adult human dose based on mg/m2, respectively) revealed no evidence of teratogenicity. There are, however, no adequate and well-controlled studies in pregnant women.
Clindamycin: FDA Category: B
(FDA Category B is defined as: Studies in laboratory animals have not demonstrated a fetal risk, but there are no controlled studies in pregnant women; or animal studies have shown an adverse effect (other than a decrease in fertility), but controlled studies in pregnant women have not demonstrated a risk to the fetus in the first trimester and there is no evidence of a risk in later trimesters.)

Aspiration Hazard
Not an aspiration hazard.

12. ECOLOGICAL INFORMATION

Ecotoxicity
No relevant studies identified.

Mobility in soil
No relevant studies identified.

Persistence/Degradability
No relevant studies identified.

Bioaccumulative Potential
No relevant studies identified.

Other adverse effects
No relevant studies identified.

13. DISPOSAL CONSIDERATIONS

Disposal Methods
Dispose of in accordance with all applicable local and national regulations.

14. TRANSPORT INFORMATION

Contact supplier for transport information.

15. REGULATORY INFORMATION

United States TSCA Inventory
This product is excluded from the US EPA Toxic Substance Control Act and is regulated under the Food, Drug and Cosmetic Act.

California Proposition 65
This product contains the following materials which the State of California has found to cause cancer, birth defects or other reproductive harm: None

SARA Title III Sect. 311/312 Categorization
None

SARA Title III Sect. 313
The following chemicals are listed in Section 313 at or above de minimis concentrations: None

16. OTHER INFORMATION

Legend
ACGIH: American Conference of Governmental Industrial Hygienists
BOD: Biological Oxygen Demand
CAS#: Chemical Abstracts Service Number
FIFRA: Federal Insecticide, Fungicide and Rodenticide Act
IARC: International Agency for Research on Cancer
LC50: Lethal Concentration 50%
LD50: Lethal Dose 50%
N/A: Denotes no applicable information found or available
NTP: National Toxicology Program
OSHA: Occupational Safety and Health Administration
PEL: Permissible Exposure Limit
STEL: Short Term Exposure Limit
TLV: Threshold Limit Value
TSCA: Toxic Substance Control Act

Revision Date: February 6, 2017
Replaces: January 30, 2012
Changes made: Updated to GHS classification.

Information Source and References
This SDS is prepared by Hazard Communication Specialists based on information provided by internal company references.

Prepared By: EnviroNet LLC.

CLINTABS is a registered trademark of Virbac AH Inc.

The information and recommendations presented in this SDS are based on sources believed to be accurate. Virbac AH, Inc. assumes no liability for the accuracy or completeness of this information. It is the user's responsibility to determine the suitability of the material for their particular purposes. In particular, we make NO WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, with respect to such information, and we assume no liability resulting from its use. Users should ensure that any use or disposal of the material is in accordance with applicable Federal, State, and local laws and regulations.